EPSILOGEN
Epsilogen, a global leader in the development of immunoglobulin E (IgE) antibodies to treat cancer, today announces that the Clinical Trial Application for the Phase Ib trial of MOv18 IgE has been approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA).
The Phase Ib study is expected to initiate later in 2024 and will evaluate the efficacy of MOv18 IgE in patients with platinum-resistant ovarian cancer (PROC).
Dr Tim Wilson, Chief Executive Officer of Epsilogen, said: “This CTA is another significant milestone for Epsilogen and the clinical development of MOv18 IgE. We look forward to progressing MOv18 IgE into a Phase Ib efficacy study later this year as we continue to demonstrate the potential of IgE antibodies as a new, differentiated class of cancer treatments.”
About MOv18 IgE
MOv18 IgE is an immunoglobulin E (IgE) antibody targeting the folate receptor alpha (FR alpha) antigen. FR alpha is present on a variety of cancers including ovarian, endometrial, lung and triple negative breast cancer. Epsilogen has successfully completed a Phase I safety study of MOv18 IgE in PROC patients. The results of the study, published in Nature Communications, found MOv18 IgE to be safe and well tolerated, with evidence of anti-tumour activity observed. Epsilogen, alongside its partner Lonza, also announced the successful completion of large-scale Good Manufacturing Practice (GMP) manufacturing of MOv18 IgE earlier this year.
About the Phase Ib study
The Phase Ib study is designed to confirm the safety and tolerability of MOv18 IgE and demonstrate efficacy in PROC. Following the dose escalation, an expansion cohort will be recruited to make a preliminary assessment of the anti-tumour activity of MOv18 IgE at a selected dose. In addition, delay to disease progression will be assessed along with a number of translational elements to generate further understanding of MOv18 IgE in the study population.
About Epsilogen Ltd
Epsilogen is a global leader in the development of immunoglobulin E (IgE) antibodies to treat cancer. IgE’s natural function is to provide immunological defence against certain parasites. This functionality makes it an ideal treatment of solid tumours due to its strong potency, enhanced tumour access and long tissue half-life.
Epsilogen’s lead product candidate, MOv18 IgE, is the first therapeutic IgE antibody to enter the clinic and encouraging data from a completed Phase I trial demonstrated MOv18 IgE to be safe and well tolerated with early signs of clinical activity. Epsilogen has recently successfully completed large scale GMP manufacture of MOv18 IgE (the first time this has been achieved for an IgE antibody) and will initiate a Phase Ib trial in platinum-resistant ovarian cancer patients later this year. The company is also developing a pipeline of IgE therapies in oncology as well as proprietary platforms including IgE bispecifics and unique IgE/IgG combination antibody molecules (IgEGs) with enhanced functionality.
Epsilogen began operations in 2017 as a spin-out of King’s College London and has attracted venture capital financing from Epidarex Capital, Novartis Venture Fund, 3B Future Health, British Patient Capital, ALSA Ventures and Schroders Capital amongst others. Find out more at epsilogen.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240707808760/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Payments Leaders Unprepared for 2026 Disruption, Warns ACI Worldwide11.12.2025 13:00:00 CET | Press release
ACI’s Top Ten Payments Predictions for 2026 urges payments leaders to act amid structural shifts in global payments Most global payments leaders lack a clear roadmap to navigate the seismic changes coming in 2026 , according to the latest Top Ten Payments Predictions from ACI Worldwide (NASDAQ: ACIW), an original innovator in global payments technology. With AI-driven intelligence, next-gen authentication, new regulatory frameworks, and soaring demand for instant, embedded, and secure payments, the industry is entering an era of structural disruption. However, ACI’s recent report Payments in Transition: Leadership in an era of transformation reveals that only 36% of payments executives have a clear long-term modernization roadmap, leaving many without a strategic vision for transformation. “In 2026, payments disruption won’t be incremental—it will be structural,” said Philip Bruno, Chief Strategy and Growth Officer at ACI Worldwide. “Real-time is now the baseline, digital assets are en
Andersen Global styrker sine vurderingskapaciteter i Asien og Stillehavsområdet med ETC11.12.2025 12:29:00 CET | Pressemeddelelse
Andersen Global fortsætter med at udvide sin tilstedeværelse i Asien og Stillehavsområdet gennem en samarbejdsaftale med Edmund Tie & Company (ETC), et full-service ejendomsrådgivningsfirma med hovedsæde i Singapore. ETC blev stiftet i 1995 og leverer vurderings- og rådgivningsydelser på tværs af ejendommens livscyklus, herunder lovpligtig og selskabsrelateret vurdering, investeringsrådgivning, feasibility-analyser og rådgivning om ejendomsskat. Med aktiviteter i Singapore, Malaysia og Thailand kombinerer ETC dybdegående regional viden med internationale standarder for at støtte udviklere, investorer, private og statslige fonde, selskaber, REIT'er samt ejere og lejere. Firmaet er kendt for sin forskningsbaserede tilgang og integrerede servicemodel og hjælper kunder med at navigere i komplekse lovgivninger og optimere værdien af deres aktiver. "Vores styrke ligger ikke kun i den tekniske udførelse, men i at hjælpe kunder med at se det fulde billede – at forbinde markedssignaler, lovgivn
AB InBev and International Cricket Council Announce Landmark Global Partnership11.12.2025 10:31:00 CET | Press release
World’s Leading Brewer becomes the Official Beer Partner of the ICC The International Cricket Council (ICC) announced AB InBev (Euronext: ABI) (NYSE: BUD) (MEXBOL: ANB) (JSE: ANH), the world’s leading brewer, will become the Official Beer Partner for all major ICC tournaments starting in 2026. The partnership will be led by Budweiser 0.0, Budweiser’s no-alcohol beer in India, with other ABI mega brands activating in Europe and Africa. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251211250826/en/ AB InBev and ICC announce global partnership From attending a match live in-stadium to watching one at a bar or pub with friends, with a lower alcohol-by-volume (ABV) and no-alcohol options like Budweiser 0.0, beer is the natural choice to enjoy responsibly. Through this partnership with the ICC, AB InBev will create more moments of cheers, choice and celebration for cricket fans of legal drinking age all over the world. ICC CEO, S
Spark Reply and Concept Reply Promote CO₂-optimised Charging Together With BMW11.12.2025 10:30:00 CET | Press release
Spark Reply, specialists in design and user experience, and Concept Reply, IoT and AI technology experts within the Reply Group, have developed a smart app for the BMW group as part of a research project that actively encourages electric vehicle drivers to adopt low-carbon charging habits. The “COOL” feature within the BMW Prototyping App “360° Mobility” analyses the current electricity mix and shows users in real time when it is at its cleanest. Playful interactions and personalised AI-generated images further motivate drivers to make more sustainable choices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251211155452/en/ In a post pilot survey, 73 per cent of participants stated that they were willing to make an extra effort to charge with reduced CO₂ emissions, such as by setting a charging window in their app. This proves that 'COOL' can measurably reduce the carbon footprint of everyday electric driving. Electric mobil
Thales Launches AI Security Fabric, Providing AI Runtime Security for Agentic AI and LLM-Powered Applications11.12.2025 09:00:00 CET | Press release
Thales launches its new AI Security Fabric, delivering the first runtime security capabilities designed to protect Agentic AI, LLM-powered applications, enterprise data, and identities.New capabilities address emerging AI-specific threats—including prompt injection, data leakage, model manipulation, and insecure RAG pipelines—helping organizations innovate safely while maintaining compliance.With upcoming 2026 enhancements, Thales aims to provide a comprehensive security layer for AI ecosystems, enabling enterprises to confidently scale AI adoption across cloud and on-premises environments. AI is one of the fastest-growing technologies in the history of modern business, with the ability to revolutionize industries, optimize operations, and drive innovation, but it is also introducing security gaps, risks, and vulnerabilities. According to McKinsey, 78% of organizations are using AI in at least one business function, up from 55% two years ago. As a result, 73% of them are investing in A
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom